Therion Biologics Contact UsSitemapHome
Company Overview Science Clinical Trials Patient Resources Press Room
Press Room

Corporate Backgrounder (PDF)

Home > Press Room > Company News

News

June 29, 2006 Therion Reports Results of Phase 3 PANVAC-VF Trial
Company Sale Plan Is Announced

June 3, 2006 Therion Reports Results of Phase 2 PROSTVAC�-VF Trial at ASCO Annual Meeting and Formalizes Plan for an NCI-Sponsored Phase 3 Study
Potential Survival Difference Identified in Phase 2 Study

June 1, 2006 Therion Biologics Announces Conclusion of PANVAC-VF Phase 3 Trial
-Presentations of Therion�s targeted immunotherapeutics to be presented at annual ASCO meeting in Atlanta-

February 10, 2006 Therion Completes Phase III Enrollment for PANVAC-VF Pancreatic Cancer Trial; BLA Planned for 2006

December 27, 2005 Therion Biologics Secures $50 Million to Complete Pivotal Clinical Development Program
Funding for Continued Commercialization Preparation

July 7, 2005 Therion Biologics Corporation Completes Enrollment in Phase II Clinical Trial of PROSTVAC�-VF in Androgen Independent Prostate Cancer

June 17, 2005 Therion Biologics Corporation Secures $30 Million in Private Equity Financing
- Appoints Kathryn Davis as Vice President, Clinical Affairs -

May 16, 2005 Therion Announces Oral Presentation of Data from Phase II PROSTVAC-VF Study in Patients with Androgen-Independent Prostate Cancer
- PROSTVAC-VF treatment associated with declines in PSA at 3 months and a clear partial tumor response for one patient at 8 months -

May 15, 2005 Therion Announces Presentation of Follow-up Clinical Data Regarding Its Novel Targeted Cancer Therapy PANVAC-VF at ASCO
- Data suggest PANVAC-VF treatment may result in prolonged overall survival for patients with advanced pancreatic cancer -

May 14, 2005 Therion Announces Oral Presentation of Clinical Data on Its Targeted Cancer Therapy PROSTVAC-VF at ASCO
- Therion�s prime/boost regimen results in favorable clinical response with stable PSA scores at 50 months -

May 11, 2005 Therion Announces Upcoming Oral and Poster Presentations at ASCO on Lead Programs in Prostate and Pancreatic Cancer

December 22, 2004 RESEARCHERS PUBLISH SUPPORTING SAFETY AND ANTI-TUMOR ACTIVITY OF THERION BIOLOGICS� CEA-TRICOM� THERAPEUTIC VACCINE IN JOURNAL OF CLINICAL ONCOLOGY
FOR IMMEDIATE RELEASE

October 29, 2004 THERION BIOLOGICS TO PRESENT AT MASS OPPORTUNITIES BIOTECHNOLOGY INVESTMENT CONFERENCE
Company to Provide Overview of Late-stage Clinical Programs in Pancreatic and Prostate Cancer

October 11, 2004 THERION BIOLOGICS TO PRESENT AT BIO EMERGING COMPANY INVESTOR FORUM
-CEO to Discuss Programs Recently Highlighted in FDA Consumer-
Press Release

July 28, 2004 THERION BIOLOGICS NAMED AMONG TOP 15 EMERGING BIOTECH COMPANIES OF 2004
Therion Biologics Represents the Future of Immunotherapy Treatments for Cancer

June 21, 2004 Therion Biologics Corporation Initiates Phase III Clinical Trial With
PANVAC-VF In Advanced Pancreatic Cancer

June 7, 2004 Researchers Present Results from Studies of Therion�s Therapeutic Cancer Vaccines in Patients with Pancreatic Cancer
-- Data presented today at ASCO (abstracts #2564 and #2513) form basis for company�s planned Phase III clinical study of PANVAC-VF --

May 24, 2004 Therion Biologics Corporation Receives FDA Agreement to Initiate Phase III Clinical Trial with PANVAC-VF in Advanced Pancreatic Cancer

December 15, 2003 Therion Biologics Obtains Rights to Biogen Idec LFA-3 Patents

November 19, 2003 Therion Begins Phase II Clinical Trial of PROSTVAC�-VF as Immunotherapy for Prostate Cancer

September 10, 2003 Massachusetts Governor Mitt Romney Today Commemorates Opening of Therion

September 8, 2003 Therion Biologics Corporation Secures $39 Million in Private Equity Financing to Advance Several Phase II Clinical Trials and Expand Manufacturing Capabilities

August 15, 2003 Scientists from the National Cancer Institute Demonstrate that Therion�s Fowlpox-Based Melanoma Vaccine Can Generate Immune Responses in Patients With Melanoma
-- Phase II clinical results reported in August issue of Clinical Cancer Research --

June 30, 2003 Therion Biologics Corporation Appoints Thomas J. Schuetz, M.D., Ph.D., as Chief Medical Officer

June 1, 2003 Georgetown Researchers Confirm Safety and Demonstrate First Evidence of Clinical Activity of Therion Biologics
-- Phase I data presented today at ASCO, Abstract #662, demonstrate enhanced immune response with addition of three co-stimulatory molecules to vaccine --
-- Dr. John Marshall of Georgetown University to highlight data at ASCO press briefing today at 2:30 pm --

March 31, 2003 Therion Biologics leases 8,400 square feet at American Twine Office Park in Cambridge

February 18, 2003 Therion Biologics Corporation Appoints Richard J. Meadows to Board of Directors

December 19, 2002 Therion Biologics and the National Institute of Allergy and Infectious Diseases, NIH, Initiate Human Clinical Trials of Preventive Smallpox Vaccine
-- Phase I Clinical Trial of TBC-MVA Smallpox Vaccine Begins --

September 17, 2002 Therion Biologics Licenses ICAM-1 from

September 9, 2002 Therion Biologics Corporation Strengthens Management Team
-- Appoints George A. Eldridge as Chief Financial Officer; Suman Patel, Ph.D. as Vice President of Quality; and Erin E. Quinn as Vice President of Human Resources --

May 19, 2002 Columbia/ECOG Researchers Stabilize PSA Levels and Clinical Progression in Prostate Cancer Patients Following Treatment with Therapeutic Vaccines
-- Phase II Data Presented at ASCO Illustrate Likely Clinical Benefit of Therion

April 3, 2002 Therion Biologics Adds to Board of Directors
-- Peter R. Wolfe, M.D., Partner and Director of Research at Pacific Oaks Medical Group, and Trudie Resch, Partner of CDP Sofinov --

March 27, 2002 Therion Names Mark Leuchtenberger, Former Vice President of Biogen International, as President and CEO
-- Dennis L. Panicali, Ph.D., Appointed to Newly Created Position of Chief Scientific Officer--

January 2, 2002 Therion Biologics and the Ludwig Institute Initiate Clinical Study of Cancer Vaccine in Europe
-- Begin Phase I Clinical Trial of Vaccine Based on ESO-1 Tumor-Associated Antigen --

November 27, 2001 Therion Biologics Strengthens Position in Cancer Immunotherapy with Acquisition of Key Patents from the U.S. Public Health Service

August 22, 2001 Therion Expands Clinical Capabilities with Appointment of Two Senior Executives
--Jeff Edelson, M.D. as Chief Medical Officer and Sr. Vice President, Clinical Development; Michael Wyand, D.V.M., Ph.D. as Sr. Vice President, Research and Development--

May 14, 2001 Georgetown Researchers Achieve Increased Cancer Patient Survival Following Treatment with Therapeutic Vaccines
-- New Data at ASCO Meeting Shows First Correlation Between Increased Immune Responses and Patient Survival with Therion vaccines --

March 20, 2001 IAVI and Therion Form Collaboration to Advance Preventative Vaccines for AIDS
-- Program Aimed at Fighting AIDS in Developing Countries --

February 20, 2001 Therion Biologics and National Cancer Institute Initiate Human Clinical Trials of Next-Generation Product for Colorectal Cancer
--Begins Phase I Clinical Trial of CEA-TRICOM Cancer Vaccine--

October 26, 2000 Therion Biologics and Aventis Pasteur Expand Cancer Vaccine Alliance
--Clinical Results Move Colorectal Cancer Products Forward--

September 7, 2000 Promising Therapeutic Vaccine for Prostate Cancer Enters Expanded Clinical Studies
--National Cancer Institute Sponsors Additional Phase II trials for Therion Biologics' PROSTVAC VF--

May 11, 2000 Therapeutic Prostate Cancer Vaccine Shows Promise in Early Clinical Study
-- Dana-Farber Cancer Institute, National Cancer Institute and Therion Biologics Report in Clinical Cancer Research Results of a Phase I Study of Therion's PROSTVAC vaccine --

February 14, 2000 Therion and National Cancer Institute Extend Collaborations

December 6, 1999 Therion Appoints Former Wyeth-Lederle Vaccines President, Ronald J. Saldarini, Ph.D., to Board of Directors

November 29, 1999 Therion Awarded AIDS Vaccine Manufacturing Contracts from NIH
--Three agreements provide over $1.5 million in funding for development of novel vaccines and research products--

November 17, 1999 Therion Appoints Richard Woodrich as Senior Vice President, Business Development

October 18, 1999 Therion Biologics and National Cancer Institute Initiate Phase II Trial of Novel Melanoma Vaccines
--Newest vaccines join Therion's cancer portfolio with additional prostate, colorectal and lung cancer products in efficacy studies--

June 28, 1999 Therion Completes $10.5 Million Financing to Accelerate Cancer Vaccine Development
-- Portfolio includes seven vaccines in Phase I and Phase II clinical trials --

September 16, 1998 Therion Obtains Rights to Novel Gene from Ludwig Institute for Cancer Vaccines
--Collaboration covers immunotherapy products based on ESO-1 tumor-associated antigen--

January 14, 1998 New Agreement to Find Cancer Vaccines
--Pasteur M�rieux Connaught (Rhone-Poulenc Group), Therion Biologics to Develop and Market Vaccines for Colorectal, Lung Cancers and Melanoma--

July 31, 1997 Francis P. Tally, M.D., Appointed to Therion Biologics Board of Directors

July 14, 1997 Therion Biologics Issued Broad U.S. Patents Covering Fundamental AIDS Vaccine Technology